+Vote!
Know More Media (Free subscription) | 11/20/2008
Eisai Co. of Japan will advance into clinical trials with a promising candidate cancer vaccine. The vaccine has no major side effects so far in a small-scale trial on roughly 40 cancer patients in the U.S. Eisai will progress to Phase I clinical trials in the U.S. in 2009. After that is will be applying to [...]
+Vote!
Nikkei (Free subscription) | 11/20/2008
Eisai Going Forward With Promising Cancer VaccineTOKYO (Nikkei)--Eisai Co. (4523) has decided to advance into clinical trials with a promising candidate cancer vaccine.
+Vote!
PR News Wire (Free subscription) | 11/10/2008
LA JOLLA, Calif., Nov. 10 /PRNewswire/ -- TorreyPines Therapeutics,
Inc. (Nasdaq: ) today announced that it has agreed to sell its
Alzheimer's disease genetics research program to Eisai Co., Ltd. for an
upfront cash payment. TorreyPines and Eisai have collaborated on the
genetics program since 2002, with the most recent agreement between the
parties concluding on September 30, 2008. The...
+Vote!
Nikkei (Free subscription) | 11/06/2008
Eisai To Sell Digestive Drug In Thailand In SE Asian PushTOKYO (Nikkei)--Eisai Co. (4523) is set to release the gastrointestinal drug Gasmotin in Thailand as early as this year with a recently fortified local sales team of 80 people -- up 10 from this spring.
+Vote!
Medical News Today (Free subscription) | 11/19/2008
The first simulation of how it feels to age decades in minutes will be run by staff from Eisai at the new University of Hertfordshire simulation centre tomorrow (19 November). The Elderly Simulation Experience, forms part of a two-day workshop designed by Eisai to provide their staff with a deeper understanding of the experiences of elderly patients.
+Vote!
SeekingAlpha.com (Free subscription) | 11/11/2008
Eben Tessari submits: TorreyPines Therapeutics, Inc. (TPTX) Tuesday announced that it has agreed to sell its Alzheimer’s disease genetics research program to Eisai Co., Ltd. for an upfront cash payment. TorreyPines and Eisai have collaborated on the genetics program since 2002, with the most recent agreement between the parties concluding on September 30, 2008. The Alzheimer’s disease...
+Vote!
Japan Times (Free subscription) | 11/10/2008
A former employee of Nomura Securities Co. and his friend pleaded guilty at the Tokyo District Court Tuesday to charges of insider stock trading. Li Yu, 31, and Su Chunguang, 38, both Chinese nationals, entered their pleas at the first hearing of their trial. Read the full story
+Vote!
PR News Wire (Free subscription) | 11/04/2008
... revenue is earned pursuant to the license agreement
entered into with MGI PHARMA (acquired by Eisai Co., Ltd. in January 2008)
during 2004, which granted the licensee exclusive rights to the
development, manufacture, commercialization and distribution of Dacogen(R)
(decitabine) for Injection. The Company recognizes royalty revenue on a
cash basis when it is received.
Excluding gain on...
